<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00517621</url>
  </required_header>
  <id_info>
    <org_study_id>ETAMINE</org_study_id>
    <nct_id>NCT00517621</nct_id>
  </id_info>
  <brief_title>Use of FACT-GOG/NTX Questionnaire in Peripheral Neurotoxicity &amp; Validation of a French Version of This Questionnaire</brief_title>
  <official_title>A Multicenter Prospective Phase II Study Evaluating Peripheral Neurotoxicity by Using FACT-GOG/NTX Questionnaire in Patients With Ovarian Cancer in Relapse Treated by Paclitaxel +/- EPO. Validation of a French Version of This Questionnaire</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ARCAGY/ GINECO GROUP</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ARCAGY/ GINECO GROUP</source>
  <brief_summary>
    <textblock>
      validation of a french version of FACT-GOG/NTX and using this questionnaire to evaluate the
      incidence of the peripheral neurotoxicity in patients treated for ovarian cancer with
      paclitaxel associated or not with EPO.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2006</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Validation of a french version of FACT-GOG/NTX of peripheral neurotoxicity questionnaire</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>- incidence and severity of the peripheral neurotoxicity according to whether the patients are treated or not by EPO</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>- variation of the rate of haemoglobin during chemotherapy</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>- Incidence of the thrombo-embolic events according to whether the patients are treated or not by EPO</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Ovarian Cancer</condition>
  <condition>Fallopian Tube Cancer</condition>
  <condition>Peritoneal Neoplasms</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EPO</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Femal patient aged &gt; 18 years

          -  Histologically proven diagnosis of cancer of the ovary, the fallopian tube or
             peritoneal

          -  patients whose disease progresses or relapses

          -  patients having received at least a line of platinum-based chemotherapy

          -  patients whose treatment of relapse is envisaged to comprise paclitaxel

          -  patients who will receive EPO for treatment of their anaemia

          -  ECOG performans status &lt; 2

          -  life expectancy &gt; 16 weeks

          -  patient who has clearly given her consent by signing on informed consent form prior to
             participation

        Exclusion Criteria:

          -  peripheral neuropathy grade &gt; 2

          -  history of ischemic cardiopathy, congestive heart failure (NYHA&gt;2), arrhythmia,
             hypertension or significant valvulopathy

          -  abnormal biological values

          -  A therapy or a serious disease which could involve a risk for the patient or interfere
             with the aims of the study

          -  patient who is pregnant, breast feeding or using inadequate contraception

          -  concomitant therapy by a potentially neurotoxic drug

          -  concomitant inclusion in another therapeutic trial which could interfere with the aims
             of the study

          -  patient who for familial, sociological, geographical or psychological condition could
             not be followed correctly
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laure COPEL, Physician</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Curie Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>HOTEL DIEU Hospital</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 16, 2007</study_first_submitted>
  <study_first_submitted_qc>August 16, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 17, 2007</study_first_posted>
  <last_update_submitted>February 24, 2011</last_update_submitted>
  <last_update_submitted_qc>February 24, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 25, 2011</last_update_posted>
  <keyword>Peritoneal cancer</keyword>
  <keyword>Relapse or progression</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Fallopian Tube Neoplasms</mesh_term>
    <mesh_term>Neurotoxicity Syndromes</mesh_term>
    <mesh_term>Peritoneal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

